- This topic has 0 replies, 1 voice, and was last updated May 4, 2023 at 8:11 am by .
Q1 results released this morning:
Unquestionably a tough quarter with a higher than expected increased in the treatment charge (+19%) and record high coke prices, combined with lower zinc prices and downtime in Turkey due to the earthquake constraining EBITDA despite strong revenue growth driven by the acquired US operations.
While there are headwinds in the short-term, our long-term thesis on this effective monopoly operator and business resilience (highlighted by the maintained dividend) remains in tact as it executes its growth strategy. We will be updating our memo shortly
- You must be logged in to reply to this topic.